Vous êtes médecin, pharmacien, interne en médecine ou biologie médicale et intéressé par les maladies auto-immunes et inflammatoires chroniques ?

Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.

The leading peer-reviewed journal dedicated to understanding of the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease, exploring key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics.

For more information, head to the ARS website.

Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.

Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!

For more information, head to the race's official website.

During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.

Click on the news to  see the video of her brilliant speech.

The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat

Nadia Merad Coliac, plastic designer, joined the NOSE (Nasal Olfactory Stemness and Epigenesis) team, as an Associate researcher. At the crossroads of several disciplines, she develops an experimental work of art and science, in the field of bioluminescence. She is considering a therapeutic application in patients with autism spectrum disorders (ASD). Recently, Nadia published Lumière vivante - Théorie et pratique de la bioluminescence (Living light - theory and use of bioluminescence) - L’Harmattan eds.

We obtained results showing the crucial role of the A2B5 epitope in the promotion of proliferation, migration, clonogenicity, and tumorigenesis of glioblastoma cells, indicating that the glycolipids recognized by the A2B5 antibody are attractive targets for glioblastoma therapy.

Many members of the INP attended the annual Canceropole PACA meeting in the Palais des Congrès of St Raphaël on the 4th and 5th of july. In the frame of the translational research call, F. Devred (INP team 9) & E. Tabouret (INP team 8) presented the results and perspective of their project "Next generation plasma profiling of gliomas using nanoDSF: toward a new prognostic and monitoring tool"

Full program available here.